

Responses to the Reviewers:

Reviewer #1:

1) The authors showed bioactive marine compounds and extracts used for treating liver diseases in Table 1. Diseases/models were shown as one of the items in Table 1. However, the authors did not perfectly show which models (mice, rat, other animal, or human) were used in some compound/extract. The authors should confirm and fix the issue.

The table has been revised and exactly marked which models that were used in the studies on marine products in the references.

2) Table 1 is shown based on the type of activity. Some compound and extract may have several activities, for example, antioxidant and anti-inflammatory. Therefore, the authors should show which type of activities the compound/extract have in another table. 3) It may doubt that the manuscript is appropriate for the publication in this journal (*World Journal of Gastroenterology*). How about for other journals regarding marine drugs?

The table has been revised now for the *World Journal of Clinical Cases*, and some of the marine products do have multiple types of bioactivities. They were shown with different mechanisms.

Reviewer #2:

1. The prevalence of liver diseases have been rising>> The prevalence of liver diseases has been rising

Thanks for the correction. The sentence has been corrected to “The prevalence of liver diseases has been rising”

2. Excessive alcohol intake can damage liver cells and cause ALD[26] >>> The cut-off amount of alcohol consumption agreed for women and men per week should be defined in this sentence.

A sentence has been added to define the cut-off amount of alcohol consumption agreed for women and men as: “The risk is increased in people who have heavy alcohol use (>3 drinks per day in men and >2 drinks in women) for >5 years.”

as the current FDA-approved drugs used to inhibit HCV replication elicit side effects.>>> as the current FDA-approved Direct Acting Antivirals (DAA), some combinations as pangenotypic, are commonly used to inhibit HCV replication with minimal side effects.

Thanks for the correction. The sentences have been corrected as “The current FDA-approved Direct Acting Antivirals (DAA) are commonly used in combinations as pangenotypic to effectively inhibit HCV replication with minimal side effects. However, the occurrence of resistance (either natural or after failure) and drug-drug interactions can limit treatment effectiveness. Natural HCV inhibitors still need to be investigated. “

hepato-protective >>>> hepatoprotective (Prefer one in seven usage, not both.)

Thanks. This has been corrected throughout the whole manuscript.

Toll-like receptor 4 (TLR4), and damage due to reactive oxygen species (ROS) play key roles in this process[49]. >>>> TLR4 abbreviation should be written in a paracentesis in Alcoholic Liver Disease section

where it is first used.

Thanks. This has been corrected as the reviewer's instruction.